GenesisCare purchases two additional ViewRay MRIdian MRI-guided radiotherapy systems for Guildford and Birmingham projects

Press releases may be edited for formatting or style | September 08, 2022 MRI Rad Oncology
DENVER, Sept. 8, 2022 /PRNewswire/ -- ViewRay, Inc. ( Nasdaq: VRAY) announced today that GenesisCare, the largest global provider of cancer services across the USA, UK, Spain and Australia, has purchased two additional MRIdian MRI-guided radiation therapy systems for installation at new-build comprehensive cancer centres in Guildford and Birmingham. These latest acquisitions will double the UK footprint to four systems, which currently includes those in Oxford and London, and will bring the total number of systems in the GenesisCare global network to six, including systems in the USA and Spain, within the next two years.

"We are passionate about partnering with companies who are driving innovation and challenging the status quo and are excited to add two further MRIdian systems to our network. This will allow us to provide even greater access to ultra-precise MRI-guided stereotactic ablative radiotherapy (SABR) across the United Kingdom," said Paul Gearing, Senior Vice President of Physician Services & Development at GenesisCare. "MR-guided adaptive SABR will be a key pillar of cancer care over the next decade and beyond, and we are proud to provide cancer patients with access to the most comprehensive and advanced treatment possible, wherever they live."

GenesisCare has more than 440 centers offering the latest treatments and technologies that have been proven to help patients achieve the best possible outcomes. For radiation therapy, that includes over 130 centers in the United States as well as 14 centers in the UK, 17 in Spain, and 40 in Australia. Every year the GenesisCare team sees more than 400,000 people globally.

United Imaging: New 80-slice CT in 2 weeks w/Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

"We are pleased to continue our partnership with GenesisCare, as well as taking part in honoring their commitment to challenging the status quo through the value of MRIdian SMART to patients in the UK, Spain and the USA," said Scott Drake, President and CEO of ViewRay.

The MRIdian system provides oncologists with outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.

To date, nearly 25,000 patients have been treated with MRIdian. Currently, 53 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.


About ViewRay:
ViewRay, Inc. ( Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


SOURCE ViewRay, Inc.

You Must Be Logged In To Post A Comment